The funding came from new and existing investors including EDB Investments Pte Ltd which is wholly-owned by the Economic Development Board (EDB), the Agency for Science, Technology and Research (A*STAR), and Mitsui & Co. Other investors include Beijing Fupu, which the Management Committee of Zhejiang Anji Economic Development Zone has an indirect majority stake in.
Singapore-headquartered Mirxes Holding Company has successfully secured US$50 million ($66.3 million) in its Series D funding round.
In its July 26 release, the company says it will use the funds to mainly scale the adoption and penetration of Mirxes’ flagship stomach cancer blood test in major Asia-Pacific (APAC) markets including Southeast Asia (SEA), China and Japan. The funds will also go towards the acceleration of the development and commercialisation of Mirxes’s maturing clinical pipeline, including a blood-based colorectal cancer screening test and the multi-cancer early detection test under Project Cadence. Project Cadence seeks to develop a single blood test for early detection of nine high mortality cancers, powered by the company’s first-in-class RNA technology and other complementary biomarker technologies.
